Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025AntibioticsOpen Access

A Comparative Study of Ceftazidime–Avibactam and Meropenem-Based Regimens in the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections in Intensive Care Units

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMurat AydınNANurten Nur AydınMAMehtap Hülya Aslan

Discussion

Loading...

Member takes

Overview

Retrospective analysis compared mortality rates and clinical outcomes in ICU patients with carbapenem-resistant gram-negative infections, suggesting both regimens had similar efficacy.

Key Points

  • Ceftazidime-avibactam and meropenem showed similar mortality rates in treating CRGNB infections.
  • 14-day, 30-day, and 90-day mortality rates were not significantly different (p values: 0.738, 0.511, 0.818).
  • Multivariate analysis identified advanced age and higher SOFA scores as predictors of increased mortality.
  • Prompt initiation of appropriate antimicrobial therapy is crucial for improving outcomes in ICU patients.

Cite This Study

Aydın et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d6477869dhttps://doi.org/10.3390/antibiotics14090863
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime–Avibactam in Critically Ill Patients: A Multicenter Observational Study2025
  2. 2Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025
  3. 3Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Klebsiella pneumoniae Resistant to All Beta-Lactame/Beta-Lactamase Inhibitor Combinations2025
  4. 4A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection2025 · 2 citations
  5. 5Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections2025